Clinical Trial: Correction of Psoriatic T Cell Signatures by Deucravacitinib
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Psoriasis Vulgaris
Study Type: INTERVENTIONAL
Official Title: Correction of Psoriatic T Cell Signatures by Deucravacitinib
Brief Summary:
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Read more